PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-23.20%
Negative net income growth while TRAW stands at 11.40%. Joel Greenblatt would see a comparative disadvantage in bottom-line performance.
3.49%
D&A growth of 3.49% while TRAW is zero at 0.00%. Bruce Berkowitz would see a mild cost difference that must be justified by expansions.
-100.00%
Negative yoy deferred tax while TRAW stands at 0.00%. Joel Greenblatt would consider near-term tax obligations but a possible advantage if competitor's deferrals become a burden later.
19.58%
SBC growth while TRAW is negative at -5.10%. John Neff would see competitor possibly controlling share issuance more tightly.
19.36%
Slight usage while TRAW is negative at -668.77%. John Neff would note competitor possibly capturing more free cash unless expansions are needed here.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
55.56%
AP growth well above TRAW's 65.22%. Michael Burry would be concerned about potential late payments or short-term liquidity strain relative to competitor.
-124.52%
Both reduce yoy usage, with TRAW at -350.42%. Martin Whitman would suspect an industry or cyclical factor pulling back on these items.
56.31%
Lower 'other non-cash' growth vs. TRAW's 270.59%, indicating steadier reported figures. David Dodd would confirm no missed necessary write-downs or gains.
-16.84%
Both yoy CFO lines are negative, with TRAW at -20.58%. Martin Whitman would suspect cyclical or cost factors harming the entire niche’s cash generation.
100.00%
Some CapEx rise while TRAW is negative at -100.00%. John Neff would see competitor possibly building capacity while we hold back expansions.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
100.00%
We have mild expansions while TRAW is negative at -100.00%. John Neff sees competitor possibly divesting or pausing expansions more aggressively.
-594.74%
We cut debt repayment yoy while TRAW is 0.00%. Joel Greenblatt sees competitor possibly lowering risk more if expansions do not hamper them.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.